For adults with CIDP stabilized on IVIg


Greater Freedom for Everyday Living

Hizentra is indicated for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.

Hizentra may help your CIDP patients address challenges with IVIg

Clinical challenges icon

Clinical challenges in CIDP:

  • In some patients, poor venous access can make IV infusion difficult1
  • Systemic adverse reactions, such as headache and fever, can occur2
Lifestyle burdens icon

Lifestyle burdens in CIDP:

  • IV infusions can be costly and constraining3
  • Travel to an infusion clinic can be time-consuming and require missing work3

*Based on equivalent dosing in grams. Hizentra may be administered in 1 or 2 infusions over 1 or 2 consecutive days.

Hizentra is:

  • A 20% immunoglobulin, half the volume of 10% IVIg*
  • Infused in smaller doses more frequently than IVIg
  • Subcutaneous, so no need to find a vein
Hizentra Volume icon

Hizentra can be:

  • Conveniently self-administered, allowing patients to infuse at an appropriate place and time
  • Infused in a median time of ~1 hour per infusion
Self-administration Time icon

Consider Hizentra for patients with CIDP who:

Have venous access issues

Experience IV-related systemic adverse reactions

Require more frequent infusions to manage their disease

Seek the flexibility, freedom, and control of self-infusing

Hizentra helped Appolos resolve his venous access issues and gave him more freedom and flexibility

Learn about support services

Below are areas you may find especially helpful when providing Hizentra to your patients.

View information about Hizentra for:


chronic inflammatory demyelinating polyneuropathy


primary immunodeficiency

You are now leaving the current website.

Do you want to continue?

No Yes